DigestRedComo funciona
Red
/
Empresas
Ob
No verificado

Obsidian Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

14 Comunicados de prensa

Ver todos los comunicados de prensa
05/08/2026
Industria
Biotecnología
Salud
Medicina - Varios
Oncología
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/08/2026
Mercado laboral
Mercado de valores
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/05/2026
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Finanzas
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
14/04/2026
Mercado de valores
Mercado laboral
Biotecnología
Farmacéutica
Salud
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/01/2026
Mercado laboral
Biotecnología
Farmacéutica
Salud
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/06/2025
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Eventos
Industria
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/04/2025
Eventos
Ferias y Congresos
Industria
Salud
Biología
Biotecnología
Medicina - Varios
Farmacéutica
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
25/04/2025
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0
23/04/2025
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
Fuente
Obsidian Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0